vimarsana.com

Page 9 - தலை வெளிப்புறம் தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Santhera to Announce 2020 Results on April 29, 2021

Investegate |Santhera Pharmaceuticals Holdi Announcements | Santhera Pharmaceuticals Holdi: Santhera to Announce 2020 Results on April 29, 2021

Santhera Reports Interim Results on Convertible Bond Exchange Offer

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Santhera Reports Interim Results on Convertible Bond Exchange Offer Santhera Pharmaceuticals Holding AGApril 20, 2021 GMT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Pratteln, Switzerland, April 20, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that so far an aggregate principal value of around CHF 39.6 million, or 66% of its CHF 60 Million Convertible Bonds, have been accepted for exchange under the Exchange Offer announced on March 25, 2021. Bondholders who have not yet accepted the Exchange Offer will be able to do so during the additional acceptance period ending on April 27, 2021, 5:00 p.m. CEST. In parallel to the Exchange Offer, voting on the bondholders’ resolution continues.

Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071

CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } }); Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee ·       With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee.    ·       MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief.     Aachen, Germany, 12 April 2021 – Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of

Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee

Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee
realwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from realwire.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.